The Ewing Family of Tumors Relies on BCL-2 and BCL-XL to Escape PARP Inhibitor Toxicity

201840 citationsJournal Article

Authors

Daniel A.R. Heisey · Virginia Cancer Institute

Timothy L. Lochmann · Virginia Cancer Institute

Konstantinos V. Floros · Virginia Cancer Institute

Colin M. Coon · Virginia Cancer Institute

Krista M. Powell · Virginia Cancer Institute

Sheeba Jacob · Virginia Cancer Institute

Marissa L. Calbert

Abstract

These data reveal BCL-2 and BCL-X<sub>L</sub> act together to drive olaparib resistance in Ewing sarcoma and reveal a novel, rational combination therapy that may be put forward for clinical trial testing.

Topics & Keywords

PARP inhibition in cancer therapy Integrated Circuits and Semiconductor Failure Analysis Advancements in Semiconductor Devices and Circuit Design

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Clinical Cancer Research

Volume 25, Issue 5, pp. 1664-1675

DOI: 10.1158/1078-0432.ccr-18-0277

Field-Weighted Citation Impact: 1.98